Secukinumab

A fully human anti-Interleukin 17-A monoclonal antibody for the treatment of moderate to severe plaque type Psoriasis.

FDA status: Approved on January,2015

Company: Novartis

Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association
0

Leave a Reply

↓